1.1Corticosteroid for inflammation control
Dexamethasone sodium phosphate dissolves in a sterile aqueous carrier. Ocular phosphatases release dexamethasone, which activates glucocorticoid receptors and reduces inflammatory signaling.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Dexamethasone sodium phosphate dissolves in a sterile aqueous carrier. Ocular phosphatases release dexamethasone, which activates glucocorticoid receptors and reduces inflammatory signaling.
A sterile epinephrine solution is diluted into an intraocular irrigation fluid before the procedure. Epinephrine stimulates alpha-adrenergic receptors in the iris dilator muscle and promotes contraction of that muscle.
Citric acid and sodium citrate establish an acidic pH during compounding. The citrate species take up or release protons as the acid load changes, reducing pH drift in the sealed vial.
Disodium edetate complexes dissolved iron and copper ions. Complexation reduces the amount of free metal available to catalyze oxidation.
The lower temperature slows temperature-dependent degradation during storage. Liquid chromatography measures both active ingredients and degradation products at filling and after one month to assess stability under refrigeration.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An ex vivo ocular test bench uses a buffer-free, chelator-free aqueous concentrate of ketorolac tromethamine and phenylephrine hydrochloride. A metering syringe introduces the concentrate into a carrier stream upstream of a cannula that perfuses the anterior chamber of an isolated porcine eye. A camera records pupil diameter, and an inline pressure transducer records perfusion pressure during exposure.
Ketorolac sodium replaces ketorolac tromethamine as the ketorolac source. The sodium salt and phenylephrine hydrochloride dissolve in water for injection, and the sodium salt mass is calculated from the target molar concentration of ketorolac. The formulation contains neither a buffer nor a chelator. Chromatographic assays measure each active and the total impurities at filling and after storage.
The same buffer-free, chelator-free aqueous blend fills glass vials at nominal liquid volumes of 1 mL and 5 mL. Vial and stopper geometry set the corresponding sealed headspace volumes to 0.25 mL and 1.25 mL, giving both sizes a headspace-to-liquid ratio of 0.25. Replicate vials from each size enter the same storage chamber, and assays compare active retention and total impurities at matched sampling times.
Sealed vials of the buffer-free, chelator-free aqueous formulation undergo 15 cycles of 24 hours at 5 °C followed by 24 hours at 30 °C. Separate vials from the same fill lot remain at 25 °C for the 30-day comparison. Dedicated vials are opened at baseline and after cycles 5, 10, and 15 for pH, active content, and total impurity measurements.
A syringe pump holds the aqueous ketorolac and phenylephrine concentrate in a separate sterile fluid path. A check valve and a Y-connector join the concentrate path to the outlet line of an ophthalmic irrigation reservoir, and a static mixer sits downstream of the junction. The syringe pump meters concentrate in proportion to carrier flow and pauses dosing when carrier flow stops.
Barcoded vials of the aqueous formulation occupy assigned positions in temperature and humidity chambers. Scheduling software generates chromatographic sample sequences from vial identifiers, chamber assignments, and sampling dates. Analysis software calculates retention for each active from its time-zero assay and calculates total impurities from the integrated impurity peaks using stored response factors. The software flags retention below 98% for either active and total impurities at or above 0.5%.
Ketorolac tromethamine supplies ketorolac, and phenylephrine hydrochloride supplies phenylephrine. Both salts dissolve in water for injection to form an aqueous solution.
Dilute hydrochloric acid or sodium hydroxide adjusts the bulk solution to the target pH during compounding. The formulation contains no added buffer or chelator.
Sealed vials are stored for one month at 25 ± 2 °C and about 60% relative humidity. Liquid chromatography compares both active ingredients with their initial amounts and measures total impurities against the limits of at least 98% retention for either active or both and less than 0.5% total impurities.
patent.fyi, US 2026/0355160 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355160/, SHA-256 ca63a59dd3a6b4d91361cae30246caf336837409536e6ad42194d775c2b191f2